NCT00782301

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

A Multicenter, Randomized, Open, Comparative Trial Of Maraviroc Versus Etravirine Each In Combination With Darunavir/Ritonavir And Raltegravir For The Treatment Of Antiretroviral-Experienced HIV-1 Subjects Co-Infected With Hepatitis C And/Or Hepatitis B

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.

Conditions

• Hepatitis B
• Human Immunodeficiency Virus
• Hepatitis C, Chronic

Interventions

Type	Name	Description
DRUG	maraviroc	maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
DRUG	etravirine	etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.

Timeline

• Start date: 2009-03-01
• Primary completion: 2010-02-01
• Completion: 2010-02-01
• First posted: 2008-10-31
• Last updated: 2012-01-19

Locations

18 sites across 3 countries: United States, Canada, Poland